Article
Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial.
BMJ open - 19 May 2015
Neychev Vladimir, Steinberg Seth M, Cottle-Delisle Candice, Merkel Roxanne, Nilubol Naris, Yao Jianhua, Meltzer Paul, Pacak Karel, Marx Stephen, Kebebew Electron
Abstract excerpt
INTRODUCTION: Finding the optimal management strategy for patients with advanced, metastatic neuroendocrine tumours (NETs) of the gastrointestinal tract and pancreas is a work in progress. Sunitinib and everolimus are currently approved for the treatment of progressive, unresectable, locally advanced or metastatic low-grade or intermediate-grade pancreatic NETs. However, mutation-targeted therapy with sunitinib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.